Comparison of organic and conventional food and food Production. Part V: Human health – pesticide residues

publishedVersio

Impact on health when sugar is replaced with intense sweeteners in soft drinks, ‘saft’ and nectar. Opinion of Vitenskapskomiteen for mattrygghet Norwegian Scientific Commitee for Food Safety

publishedVersio

Comparison of organic and conventional food and food production. Part II: Animal health and welfare in Norway

publishedVersio

General principles for the risk assessment of “other substances” in food supplements and energy drinks. Report of the Panel on Food Additives, Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics and the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety

publishedVersio

Comparison of organic and conventional food and food Production. Part IV: Human health – hygiene and pathogens

publishedVersio

Benefit and risk assessment of breastmilk for infant health in Norway: Opinion of the Steering Committee of the Norwegian Scientific Committee for Food Safety

Source at https://vkm.no/english/riskassessments/allpublications/benefitandriskassessmentofbreastmilkforinfanthealthinnorway.4.27ef9ca915e07938c3b2a6df.html.Breastmilk covers all the nutritional needs of the infant the first months of life, with the exception of vitamin D. In addition, breastmilk has a number of protective properties. However, as humans are exposed to polluting chemicals through food, air, water and skin contact, breastmilk also contains contaminants. Taking the present-day levels of contaminants in Norwegian breastmilk and the long duration of breastfeeding (12 months) in Norway into account, the Norwegian Scientific Committee for Food Safety concludes that contaminants poses a low risk to Norwegian infants, and that the benefits of breastmilk to Norwegian infants clearly outweigh the risk presented by contaminants

Risikovurdering av ”energidrikker” med koffein, taurin, glukuronolakton, inositol og vitaminer.

publishedVersio

Når barnet ditt får diabetes type 1; foreldrenes opplevelser fra diagnosetidspunktet og den første tiden.

Bakgrunn: Over 300 barn under 15 år får diabetes hvert år. Foreldrene opplever ofte bekymringer for barnet, og usikkerhet i forhold til hvordan de skal takle situasjonen både i forhold til barnet og omgivelsene

Chemotherapy-Induced Peripheral Neuropathy and Physiotherapy

Introduction:The trend with continuing increase in cancer incidence, more advanced treatment and higher survival rates results in an increasing number of survivors with possibly long-term adverse effects from the cancer treatment. Chemotherapy-induced peripheral neuropathy (CIPN) represents one of many adverse effects related to cancer treatment. So far guidelines for testing and treatment are almost absent. Thus, there is a demand for competence among physiotherapists concerning tests and treatment within this area. The aim of this article is to give an account of present knowledge of CIPN and to present relevant methods of assessment. Main section:Neurotoxic chemotherapy, which is used in treatment of cancer, is mainly vinca-alkaloids, taxanes and cisplatin. The adverse effects of the treatment may give CIPN, mainly limited to sensory functions with paresthesias as numbness, pain or other disturbed sensibilities in the peripheral part of the limbs. Furthermore, motor functions can also be impaired and can affect the postural control (balance) and thereby an increased risk of fall. A questionnaire and different physical tests measuring strength, balance and physical function are presented. Conclusion:Systematic surveys to identify CIPP symptoms, including both self-report and clinical tests are important aspects of physiotherapy for these patients. There is a demand for research in this area, including tools for both testing and treatment of CIPN

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial

Background Vacc-4x, a Gag p24-based therapeutic HIV vaccine, has been shown to reduce viral load set-points after intradermal administration. In this randomized controlled pilot study we investigate intranasal administration of Vacc-4x with Endocine as adjuvant. Methods Safety and immunogenicity were tested in patients on effective ART. They were randomized to low, medium or high dose Vacc-4x or adjuvant alone, administered four times at weekly intervals with no booster. Vacc-4x-specific T cell responses were measured in vitro by proliferation and in vivo by a single DTH skin test at the end of study. Nasal and rectal mucosal secretions were analyzed for Vacc-4x-specific antibodies by ELISA. Immune regulation induced by Vacc-4x was assessed by functional blockade of the regulatory cytokines IL-10 and TGF-ß. Results Vacc-4x proliferative T cell responses increased only among the vaccinated (p=0.031). The low dose group showed the greatest increase in Vacc-4x CD8+T cell responses (p = 0.037) and developed larger DTH (p = 0.005) than the adjuvant group. Rectal (distal) Vacc-4x IgA and IgG antibodies also increased (p = 0.043) in this group. In contrast, the high dose generated higher nasal (local) Vacc-4x IgA (p = 0.028) and serum IgG (p = 0.030) antibodies than the adjuvant. Irrespective of dose, increased Vacc-4x CD4+T cell responses were associated with low proliferation (r = -0.82, p<0.001) and high regulation (r = 0.61, p = 0.010) at baseline. Conclusion Intranasal administration of Vacc-4x with Endocine was safe and induced dose-dependent vaccine-specific T cell responses and both mucosal and systemic humoral responses. The clinical significance of dose, immune regulation and mucosal immunity warrants further investigation